Ahead of next Tuesday's earnings release, Pfizer seems undervalued based on current price of $26.55 & valuation of $150bn. But is it madness to expect upside? Quite possibly it is. My DCF analysis ...
New Haven-based Arvinas Inc. announced it will work with Pfizer Inc. to find a third-party partner to commercialize their jointly developed breast cancer drug candidate, while also cutting jobs and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results